- Trial phase
- Phase 2
- Time to market
- Efarindodekin alfa is in Phase 2 testing. Assuming successful trials and regulatory review, potential approval would likely be several years away (2029 or later), though the Gilead partnership could accelerate development if Gilead exercises its option.
- Why 3/10
- No hard dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for efarindodekin alfa within the next ~12 months. The Phase 2 trial is ongoing with no announced data readout date. The drug is one of several pipeline assets at Xilio, which also includes XTX501 (Phase 1/2, data expected Q4 2027) and XTX602 (preclinical).
Efarindodekin alfa (XTX301) is in an ongoing Phase 2 monotherapy trial with no announced data readout date. The next major pipeline catalyst for Xilio is the XTX501 Phase 1 data expected in Q4 2027. Investors should watch for any update on XTX301 Phase 2 enrollment progress or potential Gilead exercise of its option to take over development, which would trigger a $75 million transition fee.
Price Chart
Executive Summary
Efarindodekin alfa (XTX301) is Xilio Therapeutics' tumor-activated (masked) IL-12 immunotherapy, currently in a Phase 1/2 clinical trial for advanced solid tumors. Phase 1 data presented in late 2025 showed promising monotherapy anti-tumor activity and a well-tolerated safety profile at doses over 100-fold higher than the maximum tolerated dose of recombinant human IL-12. The Phase 2 portion was initiated in September 2025. The program is partnered with Gilead Sciences under an exclusive license agreement that includes a $17.5 million milestone already achieved and a potential $75 million transition fee if Gilead exercises its option. Xilio's stock trades at $8.53 with a mean analyst price target of $18, but the drug has no announced near-term data readout catalyst.
How It Works
Efarindodekin alfa is a "masked" version of interleukin-12 (IL-12), a naturally occurring protein that stimulates the immune system to attack cancer cells. The masking technology keeps the drug inactive until it reaches the tumor environment, where enzymes activate it. This design aims to deliver the potent anti-cancer effects of IL-12 while avoiding the severe side effects that have historically limited this approach.
Trial Status
The Phase 2 portion of a Phase 1/2 clinical trial was initiated in September 2025, evaluating efarindodekin alfa as a monotherapy in patients with advanced solid tumors. Phase 1 dose escalation data were presented at the SITC 2025 annual meeting, demonstrating a favorable safety profile and early signs of anti-tumor activity.
The Two-Sided Case
Upcoming Catalysts
- No specific data readout date has been announced for the XTX301 Phase 2 trial. The next major pipeline catalyst for Xilio is initial Phase 1 data for XTX501, expected in the fourth quarter of 2027. Gilead's decision on whether to exercise its option to take over efarindodekin alfa development (triggering a $75M transition fee) is a potential binary catalyst but has no announced timeline.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Xilio Therapeutics, Inc. PRESS-RELEASE XLO ·Originating report